卵巣がん診断の世界市場（2022年～2029年）

当レポートでは、世界の卵巣がん診断市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 市場の内訳：診断タイプ別
• 市場の内訳：がんタイプ別
• 市場の内訳：エンドユーザー別
• 市場の内訳：地域別

第4章 市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 業界分析

• サプライチェーン分析
• 価格分析
• アンメットニーズ

第6章 COVID-19分析

• 市場のCOVID-19分析
  • COVID-19以前の市場シナリオ
  • 現在のCOVID-19の市場シナリオ
  • COVID-19以後の市場シナリオ/将来の市場シナリオ
• COVID-19における価格の力学
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 世界の卵巣がん診断市場：診断タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：診断タイプ別
  • 市場魅力指数：診断タイプ別
• イメージング*
  • 超音波
  • CTスキャン
  • MRIスキャン
  • PETスキャン
  • その他
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
• 血液検査
  • CA125
  • HER2
  • BRCA
  • CEA
  • ER・PR
  • KRAS変異
  • その他
• 生検
• その他

第8章 世界の卵巣がん診断市場：がんタイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：がんタイプ別
  • 市場魅力指数：がんタイプ別
• 上皮腫瘍*
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
• 間質細胞腫瘍
• 胚細胞腫瘍
• その他

第9章 世界の卵巣がん診断市場：エンドユーザー別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：エンドユーザー別
  • 市場魅力指数：エンドユーザー別
• 病院*
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
• がん診断センター
• その他

第10章 世界の卵巣がん診断市場：地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）：地域別
  • 市場魅力指数：地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東とアフリカ

第11章 競合情勢

• 主な開発と戦略
• 企業シェア分析
• 製品のベンチマーク
• 注目すべき主要企業のリスト

第12章 企業プロファイル

• F. Hoffmann-La Roche Ltd.*
  • 企業概要
  • 製品ポートフォリオおよび説明
  • 主要ハイライト
  • 財務概要
• Siemens Healthcare GmbH
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific
• Abbott
• Myriad Genetic Laboratories, Inc.
• Foundation Medicine, Inc.
• Laboratory Corporation of America Holdings

第13章 世界の卵巣がん診断市場－DataM

• 付録
• 当社・アプリケーションについて
• 問い合わせ先

Market Overview

The global ovarian cancer diagnostics market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Ovarian cancer is the abnormal development of cells in the ovaries. The cells reproduce rapidly and can penetrate and destroy healthy body tissue. Patients with Epithelial ovarian cancer, Stromal tumors, and Germ cell tumors have different types of ovarian cancer depending on the type of cell where cancer starts. These tests and methods are used to detect ovarian cancer early on.

Market Dynamics

A novel biosensor for monitoring ovarian cancer tumors is expected to drive market growth.

Carcinoma antigen 125 (CA 125) has been identified as a clinical glycoprotein/biomarker for ovarian cancer early diagnosis. As a result, accurate CA 125 assessment is critical for cancer diagnosis and management. A new biosensor was developed to detect the CA 125 biomarker in human plasma samples. The anti-CA 125 antibodies were bound on the surface of a matrix containing Ag-DPA-GQD conductive nano-ink modified CysA-Au NPs (silver nanoparticles placed on D-penicillamine-functionalized graphene quantum dots). Field emission scanning electron microscopy (FE-SEM) and energy dispersive spectroscopy examined the electrode's surface morphology (EDS). Transmission electron microscopy examined the nano-ink production (TEM) mechanism. Differential pulse voltammetry (DPV) was also used to track the creation of an antigen-antibody complex. For detecting the CA 125 biomarker, the designed immunosensor performed well, with excellent specificity and sensitivity. Therefore, based on the results, it is concluded that this immunosensor promisingly has the potential to be employed in the early detection of ovarian cancer in clinical studies.

Restraint:

The high cost of diagnosis and the adverse effects of the treatment are the major factors expected to hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has adversely impacted healthcare systems and the market. The oncology community faces unprecedented challenges as the world grapples with the coronavirus illness catastrophe of 2019. Patients with ovarian cancer (OC) have been affected by a delay in diagnosis, surgery, chemotherapy, radiation therapies, and oncology follow-ups conducted by telemedicine rather than in-person appointments during this difficult period. OC patients and their doctors weigh the risks of COVID-19 and cancer treatment against postponing cancer treatment. Women with OC have reported higher levels of cancer fear, anxiety, and depression due to the delay in treatment therapy.

Moreover, traveling to clinics can increase social contact, making these patients more prone to SAR-CoV-2 infection than the general population, which can better quarantine at home. As a result of the COVID-19 pandemic's reduced access to care, the work-up process has slowed even more. There has been a significant decrease in the number of urgent referrals. Furthermore, because of the pandemic's rapid progression in the months following its emergence, physicians and hospitals quickly respond to the crisis and establish a recovery plan to address patient diagnosis and management challenges.

Segment Analysis

Imaging segment is expected to hold the largest market share in ovarian cancer diagnostics market

The imaging segment is expected to dominate in 2020. The segment's growth benefits because of the growing importance of early cancer detection and staging. Imaging diagnostics are critical in diagnosing and treating ovarian cancer because they allow doctors to see how far the tumors have progressed. The primary imaging tool for viewing and measuring the size of a tumor internally is still transvaginal ultrasonography. Although CT scans are preferable for cancer staging, they are only appropriate for tiny tumors. More advanced imaging techniques such as MRI and PET scans are performed to detect metastases and the severity of the disease. Therefore, it has increased the demand for diagnostic imaging, due to which the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ovarian cancer diagnostics market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of ovarian cancer, rising geriatric population, rising awareness, favorable government initiatives, and prominent players in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to NCI's Surveillance, an estimated 21,410 women in the United States will be diagnosed with ovarian cancer, and 13,770 are expected to die from the disease in 2021. In contrast, according to the American Cancer Society estimates for ovarian cancer in the United States, by 2022, about 19,880 women will receive a new diagnosis of ovarian cancer, and about 12,810 women will die from ovarian cancer.

Moreover, cancer mainly develops in older women. About half of the women diagnosed with ovarian cancer are 63 years or older. It is more common in white women than African American women. The American Association for Cancer Research (AACR) hosted the AACR Virtual Special Conference on Ovarian Cancer in September 2021. The American Association for Cancer Research is dedicated to assisting the ovarian cancer workforce and people living with ovarian cancer. The AACR's Biennial Special Conference on Ovarian Cancer will be held for this year's seventh time, and September is Ovarian Cancer Awareness Month. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Abbott, Myriad Genetic Laboratories, Inc., Foundation Medicine, Inc. and Laboratory Corporation of America Holdings.

Abbott Laboratories:

Overview:

Abbott Laboratories (Abbott) develops manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.

PathVysion HER-2 DNA Probe Kit: The PathVysion HER-2 DNA Probe Kit (PathVysion Kit) is designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens.

Why Purchase the Report?

Visualize the composition of the ovarian cancer diagnostics market segmentation by diagnosis method, cancer type, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in ovarian cancer diagnostics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of ovarian cancer diagnostics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global ovarian cancer diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Diagnosis Type
• 3.2. Market Snippet by Cancer Type
• 3.3. Market Snippet by End User
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. A novel biosensor for monitoring ovarian cancer tumors is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. The high cost of diagnosis and the adverse effects of the treatment are the major factors expected to hamper the market growth in the forecast period.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis
• 5.3. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Diagnosis Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 7.1.2. Market Attractiveness Index, By Diagnosis Type Segment
• 7.2. Imaging*
  • 7.2.1. Ultrasound
  • 7.2.2. CT Scan
  • 7.2.3. MRI Scan
  • 7.2.4. PET Scan
  • 7.2.5. Others
  • 7.2.6. Introduction
  • 7.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Blood Test
  • 7.3.1. CA125
  • 7.3.2. HER2
  • 7.3.3. BRCA
  • 7.3.4. CEA
  • 7.3.5. ER & PR
  • 7.3.6. KRAS Mutation
  • 7.3.7. Others
• 7.4. Biopsy
• 7.5. Others

8. By Cancer Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.1.2. Market Attractiveness Index, By Cancer Type Segment
• 8.2. Epithelial Tumor*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Stromal Cell Tumor
• 8.4. Germ Cell Tumor
• 8.5. Others

9. By End user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.1.2. Market Attractiveness Index, By End user Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Cancer Diagnostic Centers
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. F. Hoffmann-La Roche Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Siemens Healthcare GmbH
• 12.3. Quest Diagnostics Incorporated
• 12.4. Thermo Fisher Scientific
• 12.5. Abbott
• 12.6. Myriad Genetic Laboratories, Inc.
• 12.7. Foundation Medicine, Inc.
• 12.8. Laboratory Corporation of America Holdings

LIST NOT EXHAUSTIVE

13. Global Ovarian Cancer Diagnostics Market - DataM

• 13.1. Appendix
• 13.2. About Us and Applications
• 13.3. Contact Us